Hudson Valley Investment Advisors Inc. ADV decreased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 18.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,510 shares of the biopharmaceutical company’s stock after selling 2,916 shares during the quarter. Hudson Valley Investment Advisors Inc. ADV’s holdings in Bristol-Myers Squibb were worth $647,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Diversify Wealth Management LLC grew its position in Bristol-Myers Squibb by 9.6% in the 3rd quarter. Diversify Wealth Management LLC now owns 12,837 shares of the biopharmaceutical company’s stock worth $681,000 after purchasing an additional 1,122 shares during the last quarter. Pinnacle Associates Ltd. grew its position in Bristol-Myers Squibb by 36.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 266,041 shares of the biopharmaceutical company’s stock worth $13,651,000 after purchasing an additional 70,905 shares during the last quarter. First Trust Direct Indexing L.P. grew its position in Bristol-Myers Squibb by 54.8% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 33,428 shares of the biopharmaceutical company’s stock worth $1,730,000 after purchasing an additional 11,831 shares during the last quarter. Gimbal Financial bought a new position in Bristol-Myers Squibb in the 3rd quarter worth about $208,000. Finally, Pathway Financial Advisers LLC grew its position in Bristol-Myers Squibb by 38,392.1% in the 3rd quarter. Pathway Financial Advisers LLC now owns 431,112 shares of the biopharmaceutical company’s stock worth $22,306,000 after purchasing an additional 429,992 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.
Bristol-Myers Squibb Stock Performance
NYSE:BMY opened at $52.68 on Thursday. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. The firm has a market capitalization of $106.79 billion, a PE ratio of -16.99, a PEG ratio of 13.75 and a beta of 0.46. The firm’s fifty day simple moving average is $50.98 and its 200 day simple moving average is $46.48. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $55.03.
Bristol-Myers Squibb Dividend Announcement
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the stock. BMO Capital Markets reiterated a “market perform” rating and issued a $48.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 23rd. Jefferies Financial Group raised their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Sanford C. Bernstein initiated coverage on shares of Bristol-Myers Squibb in a report on Thursday, October 17th. They set a “market perform” rating and a $56.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday, July 23rd. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $52.38.
Get Our Latest Research Report on Bristol-Myers Squibb
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Stories
- Five stocks we like better than Bristol-Myers Squibb
- The Most Important Warren Buffett Stock for Investors: His Own
- Applied Materials vs ASML: Which is the Best Chip Stock to Own?
- What Is WallStreetBets and What Stocks Are They Targeting?
- Top Bill Gates Stock Picks Every Investor Should Know About
- Business Services Stocks Investing
- Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.